Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms

International Journal of Clinical Practice

Volumn 64, Issue 5, 2010, Pages 584-593

  Van Kerrebroeck, P E V ^a   Heesakkers, J ^b   Berriman, S ^c   Padmanabhan Aiyer, L ^c   Carlsson, M ^c   Guan, Z ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FESOTERODINE; TOLTERODINE;

ADULT; ARTICLE; BACKACHE; BLADDER; BLADDER DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLUENZA; LONG TERM CARE; MALE; OPEN STUDY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SATISFACTION; URINARY TRACT INFECTION; XEROSTOMIA;

ADULT; AGED; ATTITUDE TO HEALTH; BENZHYDRYL COMPOUNDS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 77949419424     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02361.x     Document Type: Article

References (35)

1. Abrams P, Artibani W, Cardozo L et al. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006; 25: 293.
2. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-15.
3. Hu TW, Wagner TH, Bentkover JD et al. Estimated economic costs of overactive bladder in the United States. Urology 2003; 61: 1123-8.
4. Coyne KS, Sexton CC, Irwin DE et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 1388-95.
5. Andersson KE, Chapple CR, Cardozo L et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19: 380-94.
6. Pfizer Inc. Toviaz® (fesoterodine fumarate). New York, NY: Full Prescribing Information, Pfizer Inc, 2007.
7. Cawello W, Auer S, Hammes W et al. Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch Pharmacol 2002; 365: R110.
8. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 1787-96.
9. Malhotra BK, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008; 46: 556-63.
10. Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12.
11. Nitti V, Dmochowski R, Sand P et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178: 2488-94.
12. Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008; 102: 56-61.
13. Khullar V, Rovner ES, Dmochowski R et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008; 71: 839-43.
14. Chapple CR, Van Kerrebroeck PE, Junemann KP et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008; 102: 1128-32.
15. Herschorn S, Swift S, Guan Z et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010; 105: 58-66.
16. Wyndaele JJ, Goldfischer ER, Morrow JD et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 2009; 63: 560-7.
17. Dmochowski RR, Peters KM, Morrow JD et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2010; 75: 62-8.
18. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005; 8: 495-505.
19. Shaya FT, Blume S, Gu A et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005; 11: S121-9.
20. Benner JS, Nichol MB, Rovner ES et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2009; [Epub ahead of print] doi:10.1111/j.464-410X.2009.09036.x.
21. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-9.
22. Donovan J, Badia X, Corcos J et al. Committee 6: symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Plymouth, UK: Plymbridge Distributors, Ltd, 2002: 267-316.
23. Avery K, Donovan J, Peters TJ et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004; 23: 322-30.
24. Kelleher CJ, Pleil AM, Reese PR et al. How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder. Br J Obstet Gynaecol 2004; 111: 605-12.
25. Chapple CR, Khullar V, Gabriel Z et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62.
26. Haab F, Corcos J, Siami P et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006; 98: 1025-32.
27. Haab F, Cardozo L, Chapple C, Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-84.
28. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002; 41: 588-95.
29. Abrams P, Malone-Lee J, Jacquetin B et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001; 18: 551-60.
30. Dwyer P, Kelleher C, Young J et al. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourol Urodyn 2008; 27: 540-7.
31. Kelleher CJ, Kreder KJ, Pleil AM et al. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8: S616-30.
32. Noe L, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface 2004; 17: 54-60.
33. D'Souza AO, Smith MJ, Miller LA et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008; 14: 291-301.
34. Shaya FT. Compliance with medicine. Ophthalmol Clin North Am 2005; 18: 611-7.
35. Van Leeuwen JHS, Castro R, Busse M, Bemelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006; 50: 440-53.